Yahoo · Aug 6, 2026
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Cytek Biosciences, Inc.'s Q2 2026 earnings call
CT
NASDAQ · CTKB
Cytek Biosciences, Inc.
Healthcare · Medical - Devices
$4.81
Up+$0.15 (+3.22%)
Updated Aug 22, 2026, 3:46 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 636.75M
- P/E ratio
- -98.76
- Dividend yield
- 0.00%
- 52-week range
- $3.28 – $6.18
- Volume
- 820.26K
- Avg. volume
- 1.17M
Price performance
CTKB price history
1M range · 21 trading sessions · Daily adjusted prices
CTKB closed at $4.81 after 21 trading sessions, up 7.85% for the selected period.
- Last close
- $4.81
- Period change
- +7.85%
- Period low
- $4.16
- Period high
- $4.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $4.69 | $4.83 | $4.59 | $4.81 | 820.26K |
| Aug 20, 2026 | $4.63 | $4.78 | $4.615 | $4.66 | 800.61K |
| Aug 19, 2026 | $4.67 | $4.92 | $4.67 | $4.70 | 1.04M |
| Aug 18, 2026 | $4.77 | $4.77 | $4.60 | $4.67 | 713.32K |
| Aug 17, 2026 | $4.66 | $4.76 | $4.57 | $4.74 | 497.83K |
| Aug 14, 2026 | $4.84 | $4.935 | $4.6614 | $4.69 | 927.48K |
| Aug 13, 2026 | $4.82 | $4.925 | $4.76 | $4.89 | 1.02M |
| Aug 12, 2026 | $4.70 | $4.80 | $4.65 | $4.78 | 846.43K |
| Aug 11, 2026 | $4.67 | $4.82 | $4.53 | $4.74 | 1.17M |
| Aug 10, 2026 | $4.315 | $4.67 | $4.16 | $4.66 | 1.22M |
| Aug 7, 2026 | $4.17 | $4.2385 | $4.115 | $4.20 | 616.08K |
| Aug 6, 2026 | $4.37 | $4.40 | $4.045 | $4.16 | 1.43M |
| Aug 5, 2026 | $4.27 | $4.31 | $4.115 | $4.18 | 993.96K |
| Aug 4, 2026 | $4.28 | $4.3618 | $4.17 | $4.28 | 819.18K |
| Aug 3, 2026 | $4.31 | $4.35 | $4.185 | $4.31 | 889.84K |
| Jul 31, 2026 | $4.28 | $4.31 | $4.135 | $4.22 | 608.89K |
| Jul 30, 2026 | $4.38 | $4.38 | $4.24 | $4.31 | 525.93K |
| Jul 29, 2026 | $4.46 | $4.55 | $4.33 | $4.38 | 597.78K |
| Jul 28, 2026 | $4.45 | $4.565 | $4.43 | $4.46 | 713.04K |
| Jul 27, 2026 | $4.46 | $4.53 | $4.365 | $4.41 | 521.4K |
| Jul 24, 2026 | $4.60 | $4.62 | $4.44 | $4.46 | 597.21K |
Latest CTKB news
The latest Smart Investors Daily articles mentioning CTKB.
Stock researchCompany · Overview
CTKB research
Overview
Company profile and research snapshot.
Company profile
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Stephens & Co. | Overweight | — |
| May 12, 2026 | Morgan Stanley | Equal-Weight | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Nov 11, 2025 | Piper Sandler | Overweight | — |
| May 28, 2025 | Morgan Stanley | Equal-Weight | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsMark MeehanWenbin Jiang - President, CEO & Chairman...
SeekingAlpha · Aug 6, 2026
Cytek Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-06. The following slide deck was published by Cytek Biosciences, Inc.
Yahoo · Aug 6, 2026
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...
Cytek Biosciences Inc (CTKB) delivers solid Q2 2026 results with 6% revenue growth, launches the industry-first Borealis 60-color system, and raises full-year guidance despite EMEA softness.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
